Back to episode — Episode 1552 Scott Adams - Lots of Bombshells and Amazing Stories Today. Don't Miss it
Context —
right thing to do. So we need to know more about this. But I would rank this as maybe my best prediction. Would anybody disagree? Name anybody else who a year ago was telling you it had to be corruption. Name anybody else who said that in public. You know somebody who talks about this stuff, but I think I'm the only one. I identified this a year in advance, and to me it was obvious from the start…
← Previous segment →that's inevitable. But our march toward full cyborg status is well underway. I would say that's not going to happen anytime soon, but it's going to happen. Contact lenses that are little computer screens.
The U.S. economy added over half a million jobs, and unemployment rate fell to 4.6 percent. Let me tell you everything you need to know about economics. You ready? Here's everything you need to know about economics. Supply and demand. Number two, if unemployment looks good, everything else is probably pretty good too. Now there could be exceptions, but generally speaking, if your employment rate is going in the right direction or it's already low, things are going to work out.
Now we have an unusual situation with massive debt and pandemics and stuff, so there could be some black swan situation going on here. But if you see the unemployment rate at 4.6 when there's inflation — it's still a little higher than you want it, right? But we also have a little more inflation than we want. So unemployment works to lower inflation because there'll be more people to offer themselves for the jobs. So this is a really, really healthy number. Good news. Doesn't mean we're out of the woods, but that's the real good news.
Well, in other news, the pandemic is over. Sort of. Almost. Kind of. And it goes like this. The UK is the first country to approve an antiviral pill. So a pill that you would take once you suspected you had COVID symptoms, and it would directly work against the virus. And the UK says it could be a game changer. So they think it's a big, big deal. And this is developed by Merck and Ridgeback Biotherapeutics.
Here's why I think this is a bigger deal than you do, and you probably think it's a pretty big deal. You know our big controversy about vaccination or no vaccination. It's like all we want to talk about. And you know that the pharma companies owned the news. You knew that, right? Big Pharma is the big advertiser for the news, so the news is not going to run stories that are directly horrible to their biggest advertisers. You know, human nature. Follow the money. It's just not going to happen. They'd have to do it if other people were reporting it, but you're not going to see one of the major news companies break a story about a pharma company. I don't think that's ever going to happen, not if they also advertise.
So here's what's important. Until we get these approved — these tablets that you can take — until we get them, what does the pharma i
Context —
ndustry in this country have to sell? Well, in this country they can sell you some monoclonal antibodies, and they're making them as fast as we're using them, I think. So there's that. But also vaccinations, of course. So vaccinations are the primary money competitor to therapeutics, right? Vaccines are the competition for therapeutics. They're not the same, and I'm not recommending you do one or…
Next segment → →